March 25, 2025[et_pb_section fb_built="1" admin_label="section" _builder_version="4.16" da_disable_devices="off|off|off" global_colors_info="{}" da_is_popup="off" da_exit_intent="off" da_has_close="on" da_alt_close="off" da_dark_close="off" da_not_modal="on" da_is_singular="off" da_with_loader="off" da_has_shadow="on"][et_pb_row admin_label="row" _builder_version="4.16" background_size="initial" background_position="top_left" background_repeat="repeat"…
January 21, 2025
November 11, 2024First interventional study designed to demonstrate the clinical utility of the TriVerity test and its impact on patient management Sunnyvale,…- October 10, 2024Sam Ajizian, MD (Chief Medical Officer), Jamie Lewis (Chief Commercial Officer), and Laura Spencer Garth (General Counsel) Hired to Advance…
October 1, 2024Sunnyvale, Calif., October 1, 2024 — Inflammatix, a pioneering molecular diagnostics company, today presented data demonstrating the high diagnostic and prognostic…- September 12, 2024Fundraise brings lead product, TriVerity™ Test, closer to commercialization following recent submission to FDA. Sunnyvale, Calif., September 12, 2024 — Inflammatix,…
- November 28, 2023Regulatory Milestone Designed to Expedite Path to FDA Clearance and CMS Coverage. Sunnyvale, Calif., November 28, 2023 — Inflammatix, Inc., a…
- November 15, 2023Company Reaches Important Product Development Milestone with its Myrna™ Instrument and TriVerity Cartridge. Sunnyvale, Calif., November 15, 2023 — Inflammatix, Inc.,…
- September 13, 2023Data-biobank Acutelines and Inflammatix, an innovative molecular diagnostics company, are joining forces to improve the early detection of sepsis: a…
- July 10, 2023Sunnyvale, Calif., July 10, 2023 — Inflammatix, a pioneering molecular diagnostics company, announced today the appointment of Heiner Dreismann, PhD, as…
